Woman's World on MSN

Normal AST levels by age: Are you at risk of fatty liver disease?

A1C, LDL, HDL… the number of medical abbreviations you might see on your patient portal is enough to make you think your ...
Le Lézard

Travere Therapeutics Provides Corporate Update and 2026 Outlook

Travere Therapeutics, Inc. today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to be approximately ...
European Medical Journal

How Can Hematologist-Oncologists Tackle Invasive Fungal Infections? Expert Insights from Clinical Practice

The diagnosis and management of invasive fungal infections in adult patients with hematological malignancies remains a ...

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Le Lézard

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Johnson & Johnson today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor ...

Johnson & Johnson: RYBREVANT (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...